Saturday 17 October 2026
Export LXEO’s income statement to Excel — free account
Lexeo Therapeutics, Inc.
LXEO Healthcare Biotechnology
Lexeo Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $654,000.00. In the quarter to June 2026, EPS grew 50.0%, free cash flow grew 35.6% and total debt fell 83.5%, each against the same quarter a year earlier.
2.64
0.12
−4.35%
Follow LXEO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 9.00 | 5.77 | 1.45 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 17.72 | 22.33 | 10.99 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 53 | 58 | 72 | 59 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 1 | 2 | 1 | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 99.19 | 100.00 | — | — | — | |||||
| EBT | — | — | — | — | (5) | (51) | (59) | (66) | (98) | (100) | |||||
| EBT margin, % | — | — | — | — | (993.79) | (3,054.84) | (9,063.76) | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | (5) | (51) | (59) | (66) | (98) | (100) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.02 | 0.06 | 0.40 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (0.19) | (1.90) | (36.36) | (12.40) | (3.09) | (1.86) | |||||
| Cash flow | — | — | — | — | (0.12) | (1.66) | (33.47) | (11.11) | (2.55) | (1.84) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.55) | (0.03) | (0.02) | (0.01) | |||||
| Free cash flow | — | — | — | — | (0.12) | (1.66) | (34.03) | (11.14) | (2.57) | (1.84) | |||||
| Book value | — | — | — | — | 0.96 | 4.86 | (69.30) | 21.21 | 3.68 | 4.60 | |||||
| Shares, m | — | — | — | — | 27 | 27 | 2 | 5 | 32 | 54 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | ||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EV/FCF | — | — | — | — | 0.22 | 0.22 | 0.22 | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (3) | (44) | (55) | (59) | (81) | (99) | ||||
| Capex | — | — | — | — | — | 0 | (1) | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | (3) | (44) | (55) | (60) | (82) | (99) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 29 | 129 | 66 | 107 | 103 | 172 | ||||
| Total debt | — | — | — | — | 3 | — | 2 | 1 | 1 | 0 | |||||
| Net debt | — | — | — | — | (26) | (136) | (76) | (120) | (121) | (181) | |||||
| Shareholders’ equity | — | — | — | — | 26 | 129 | (113) | 114 | 117 | 247 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (60.89) | (50.68) | (56.06) | (68.58) | (48.10) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (104.69) | |||||
| ROE | — | — | — | — | 0.00 | 165.60 | 70.34 | (22,855.08) | (85.37) | (55.00) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Sep 2022
Charts ten years each
Lexeo Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics, Inc. | $235.7M | — (loss-making) | 19.9× | −90.95% (below 0%: shrinking) | n/m | −59.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IMRX Immuneering Corporation | $235.5M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −74.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| QTTB Q32 Bio Inc. | $231.3M | 2.5× | — (loss-making) | −1,928.18% (below 0%: shrinking) | n/m | +71.13% (above 0%: growing) | 100.00% | 0.00% | Compare |
| FATE Fate Therapeutics, Inc. | $230.7M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| LXEO Lexeo Therapeutics, Inc. | $226.6M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | |
| SLGL Sol-Gel Technologies Ltd. | $224.9M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| GLSI Greenwich LifeSciences, Inc. | $224.9M | — (loss-making) | — | — | n/m | +13.14% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KROS Keros Therapeutics, Inc. | $220.1M | — (loss-making) | — (loss-making) | −99.83% (below 0%: shrinking) | n/m | +32.19% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PLX Protalix BioTherapeutics, Inc. | $217.5M | 10.9× | 10.2× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| Median of peers | $227.8M | — | — | −96.58% | — | +0.10% | 100.00% | 0.00% |
Lexeo Therapeutics, Inc. (LXEO) key facts
- Lexeo Therapeutics, Inc. (LXEO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Lexeo Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $654,000.00.
- As of October 16, 2026, LXEO traded at $2.64, a market capitalization of $226.6 million.
- Return on equity was −55.0% and debt-to-equity 0.00.
- Its Piotroski F-score is 4 out of 9 for fiscal 2022.